BlackRock Investment Management’s Actinium Pharmaceuticals ATNM Stock Holding History

BlackRock Investment Management’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$6K	Hold	229	–	–	﹤0.01%	3721
2016 Q3	$9K	Hold	229	–	–	﹤0.01%	3619
2016 Q2	$12K	Buy	229 +37	+19%	+$2.06K	﹤0.01%	3549
2016 Q1	$11K	Hold	192	–	–	﹤0.01%	3572
2015 Q4	$19K	Buy	192 +16	+9%	+$1.06K	﹤0.01%	3442
2015 Q3	$9K	Buy	176 +9	+5%	+$601	﹤0.01%	3721
2015 Q2	$13K	Sell	167 -2,290	-93%	-$195K	﹤0.01%	3604
2015 Q1	$182K	Buy	2,457 +431	+21%	+$51.3K	﹤0.01%	3234
2014 Q4	$358K	Buy	2,026 +5	+0.2%	+$949	﹤0.01%	3133
2014 Q3	$406K	Buy	2,021 +174	+9%	+$34.5K	﹤0.01%	3082
2014 Q2	$400K	Buy	+1,847	New	+$615K	﹤0.01%	3130

Other funds holding ATNM

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock Investment Management's ATNM Position: Q4 2016 in Review

BlackRock Investment Management held its Actinium Pharmaceuticals (ATNM) position steady in Q4 2016 at 229 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #3721.

BlackRock Investment Management first reported a position in ATNM in Q2 2014 and has held it in 11 quarters since. The position peaked at $406K in Q3 2014. 30 funds tracked by Wall St. Rank hold ATNM as of Q4 2016.

BlackRock Investment Management held 229 shares of Actinium Pharmaceuticals worth $6K as of Q4 2016.
BlackRock Investment Management left its Actinium Pharmaceuticals share count unchanged in Q4 2016.
Actinium Pharmaceuticals made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #3721 holding.
BlackRock Investment Management first reported a position in Actinium Pharmaceuticals in Q2 2014 and has held it in 11 quarters since.
BlackRock Investment Management's Actinium Pharmaceuticals position peaked at $406K in Q3 2014.
30 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.